Dimerix (ASX:DXB) is a clinical stage biotechnology company, with a focus on Phase II clinical trials for chronic kidney disease.
The company's lead clinical program, DMX 200, has been granted Orphan Drug Designation status in the U.S. for a medical condition called Focal Segmental Glomerulosclerosis (FSGS).
The innovative treatment combines two existing drugs.
Find out more from Kathy Harrison at Proactive's CEO Sessions.
Click on city below to register by email
- Melbourne: Tuesday 11th April.
- Sydney: Wednesday 12th April.
- Email Pauline here.
- Call office on (02) 9280 0700.
Presenter list
- Intermin Resources (ASX:IRC): MD Jon Price
- Southern Gold (ASX:SAU): MD Simon Mitchell
- Proteomics International Laboratories (ASX:PIQ): MD Richard Lipscombe
- Dimerix (ASX:DXB): CEO Kathy Harrison
- Novogen (ASX:NRT): CEO Dr James Garner (Presenting in Melbourne only)
- Aspire Mining (ASX:AKM): MD David Paull (Presenting in Sydney only)